Next-gen Novo Nordisk shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on its success with Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, boosting the drugmaker's shares.
Novo Nordisk Stock Jumps on Early Stage Weight-Loss Drug Trial Results
Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug.
Novo Nordisk next-gen shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, boosting the drugmaker's shares.
The New York Times13h
New York Times - Top Stories
Israel’s Cease-Fires in Lebanon and Gaza Appear Fragile Israeli forces killed at least 15 people and injured dozens more in southern Lebanon on Sunday, Lebanese officials said. In Gaza, Israel ...
Bureau of Meteorology23h
Denmark Forecast
Cloudy. Medium chance of light showers or drizzle this morning. Winds south to southwesterly 20 to 30 km/h becoming light in the late evening. Daytime maximum temperatures 24 to 29. Partly cloudy. Slight chance of a shower. Light winds becoming southerly ...
Copenhagen Post2d
New results from weight-loss drug boost Novo’s stock value
New data from a study on Novo Nordisk’s weight-loss drug, amycretin, has shown positive results. Participants in the study who received the highest dose of the drug lost an average of 22 percent of their body weight after 36 weeks.
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
THESE MEDICATIONS ARE MOSTLY KNOWN FOR TREATING DIABETES AND OBESITY.. BUT THE F-D-A HAS APPROVED THEM FOR PREVENTING HEART DISEASE AFTER STUDIES LAST FALL. THAT SHOWED ABOUT A 20% REDUCTION IN CARDIOVASCULAR EVENTS DR.
Why Novo Nordisk surged 14% on new weight-loss drug results
Shares of Danish pharmaceutical giant Novo Nordisk surged close to 14% on Friday after the company announced positive results from early-stage trials for its once-weekly obesity treatment, amycretin.
ENDPOINTS NEWS2d
No­vo Nordisk’s amy­cretin prompts 22% weight loss in ear­ly obe­si­ty tri­al
Novo Nordisk’s subcutaneous form of amycretin achieved estimated weight loss of 22% at six months in a Phase 1b/2a clinical trial, the Danish company said Friday.
Novo Nordisk shares pop on early-stage weight loss drug trial results
The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.
News Medical2d
Dapagliflozin plus calorie restriction boosts remission rates in adults with type 2 diabetes and obesity
Findings indicate that dapagliflozin and calorie restriction together improve weight loss and metabolic health, increasing the likelihood of diabetes remission.
Novo Nordisk A/S: Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly